The dinitrobenzamide mustard prodrugs, PR-104A and SN27686, for use in a novel MNDEPT cancer prodrug therapy approach

Directed enzyme prodrug therapy is a highly promising anti-cancer strategy. However, the current technology is limited by inefficient prodrug activation and the dose-limiting toxicity associated with the prodrugs being tested; to overcome these limitations, the dinitrobenzamide mustard prodrugs, PR-...

Descripción completa

Detalles Bibliográficos
Autores principales: Ball, Patrick, Thompson, Emma, Anderson, Simon, Gwenin, Vanessa, Ashoorzadeh, Amir, Smaill, Jeff, Gwenin, Chris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Portland Press Ltd. 2023
Materias:
Biotechnology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10126811/
https://www.ncbi.nlm.nih.gov/pubmed/37067816
http://dx.doi.org/10.1042/BSR20230627

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10126811/
https://www.ncbi.nlm.nih.gov/pubmed/37067816
http://dx.doi.org/10.1042/BSR20230627

Ejemplares similares